Rep. Daniel S. Goldman sold Incyte (INCY)
Rep. Daniel S. Goldman (D-NY-10) · $1K–$15K · traded Mar 6, 2023
- Transaction
- Sold
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Mar 6, 2023
- Disclosed
- Apr 17, 2023
- Days to disclose
- 42
- Asset type
- Stock
- As filed
- Incyte Corporation
- Industry
- Biotechnology · Healthcare
Other trades in this filing
All of Goldman's trades →- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$50K–$100K
Sold VONOVIA SE ADR CMN (VONOY)
$50K–$100K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought VOLKSWAGEN AKTIENGESELLSCHAFT ADR CMN (VWAPY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Sold (partial) Vodafone Group Public Limited Company VOD
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought VAT GROUP AG ADR CMN (VACNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) UPM-KYMMENE OYJ ADR CMN (UPMMY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Swedbank AB (publ) SWDBY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Sumitomo Mitsui Financial Group SMFG
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold SOMPO JAPAN NIPPONKOA HLDGS IN ADR CMN (SMPNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) Shiseido Company, Limited SSDOY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought SALMAR ASA ADR CMN (SALRY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
Recent Congress trades in INCY
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- May 31, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded May 15, 2025 · disclosed May 31, 2025
- Nov 8, 2023$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 10, 2023 · disclosed Nov 8, 2023 · Spouse
- Nov 8, 2023$1K–$15K
- Dec 8, 2018$1K–$15K
Sen. Shelley Moore Capito (R-WV)
$1K–$15K · Traded Nov 12, 2018 · disclosed Dec 8, 2018 · Spouse
- Oct 6, 2017$1K–$15K
Sen. Shelley Moore Capito (R-WV)
$1K–$15K · Traded Sep 8, 2017 · disclosed Oct 6, 2017 · Spouse
Company context for INCY
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
INCY: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
INCY: Financial results
Filed 8-K for an event or period dated 2026-10-29. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ATEBRIOZ (Zilurgisertib)
The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that ATEBRIOZ (zilurgisertib), approved September 25, 2026, manufactured by Incyte Corporation meets the criteria for a priority review voucher.
Public: Oct 28, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.